Jane Robertson
AstraZeneca
10
0
9
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Tracy Batchelor, MD
Massachusetts General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Tracy Batchelor, MD, MPH
Massachusetts General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Hideyuki Mishima, M.D., PhD
National Hospital Organization Osaka National Hospital
Shared therapeutic areas:
Worked with same sponsors:
Patricia LoRusso, DO
Wayne State University
Shared therapeutic areas:
Worked with same sponsors:
Xiaojin Shin, MD
AstraZeneca
Shared therapeutic areas:
Worked with same sponsors:
Xiaojin Shi, MD
AstraZeneca
Shared therapeutic areas:
Worked with same sponsors:
Masahiro Fukuoka, MD
Sakai hospital Kinki University School of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Tomohide Tamura, MD
National Cancer Centre Hospital, Tokyo
Shared therapeutic areas:
Worked with same sponsors:
Bijoyesh Mookerjee, MD
AstraZeneca
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
All 10 trials loaded